Drug Trials Drugs Genetics 
Bio Pharma Dive
NOVEMBER 7, 2022
Buoyed by strong mid-stage study results, the biotech will soon start a cardiovascular outcomes trial of a drug designed to target a genetic risk factor called lipoprotein(a).
Pharmaceutical Technology
JUNE 15, 2023
The need for new medical treatments and drugs has never been greater. But before pharmaceutical companies can go to market with a breakthrough drug, they need to ensure safety and efficacy through clinical trials. Even reaching the clinical trial phase offers no guarantees, as only 12% of such drugs receive U.S.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
AUGUST 25, 2022
Obesity, diabetes, and genetics are the primary drivers, and COVID is about to make this exponentially worse. But herein lies the dichotomy that medicine has created: By failing to regularly screen to find the early-stage disease, the number of patients who could participate in drug trials is limited. About the Author.
XTalks
SEPTEMBER 11, 2020
Disease doesn’t discriminate, and researchers understand different populations react differently to drugs. Why, then, are clinical trials so stubbornly homogeneous? Clinical trials, however, don’t reflect that diversity. When trial populations don’t match the broader patient base, the treatments they produce aren’t as effective.
XTalks
MAY 16, 2023
The exact cause of pulmonary fibrosis is often unknown, and in such cases, it is referred to as idiopathic pulmonary fibrosis (IPF); however, certain factors can contribute to the development of pulmonary fibrosis, including environmental and occupational exposures, certain medications, autoimmune diseases and genetic predisposition.
XTalks
FEBRUARY 25, 2022
Despite these statistics, in the US, Black people only constitute five percent of all clinical trial participants. The overwhelming majority of trial participants nationwide are white. However, the links between race-based genetics and disease are not quite clear. Personalized Medicine.
XTalks
SEPTEMBER 13, 2024
A significant initiative is the Diversity Convergence project, which brings together multiple organizations, including the Multi-Regional Clinical Trials Center of Brigham and Women’s Hospital and Harvard, FasterCures, a center of the Milken Institute and the National Academies’ Forum on Drug Discovery, Development and Translation.
Expert insights. Personalized for you.
288 
Let's personalize your content